Centenial Surgical Suture Ltd.
Snapshot View

53.90 -0.05 ▼-0.1%

29 July 2021, 04:00:00 P.M.
Volume: 2,183

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Medical Equipment/Supplies/Accessories Compare with Industry peers
Website http://www.centenialindia.com
Financial Indicators
Market Cap 19.66 Cr.
Earnings per share (EPS) 2.64 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 20.44 Trailing Twelve Months Ending 2021-03
Industry PE - Trailing Twelve Months Ending 2021-03
Book Value / Share 76.19 Trailing Twelve Months Ending 2021-03
Price to Book Value 0.71 Calculated using Price: 53.90
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 0.36 Cr. 3,648,300 Shares
FaceValue 10
Company Profile

Centenial Surgical Suture Ltd., founded in 1995, manufactures a broad range of quality sterile needled sutures, with state-of-the-art manufacturing and packaging equipment, sophisticated processes designed and operated by Centenial's competent and devoted staff. Centenial Sutures is a combination of Craftmanship, the Latest Production Technology, Strictest Quality Control, Care and Dedication, results in Products of Incomparable Quality. Centenial is a company with a Surgeon's eye for Quality. At Centenial doing business the fair way is their Foremost Concern, by Guaranteeing Courteous, Fair and Honest Service, enough inventory to meet any order size and pricing. Centenial is confident that it can prove its flexibility, capacity and attention for Quality and Consistency in manufacturing world class sutures in India. 

Centenial has introduced Good Manufacturing Practice into all aspects of production and quality control which includes the maintenance of detailed batch records, a recall system, control of procedures, staff training and a controlled production environment.

All products are manufactured to meet US Pharmacopoeia and European Pharmacopoeia and other regulatory requirements. The company proposes to have its range of sutures registered with the US Food and Drug Administration as manufacturer of sterile absorbable and non absorbable sutures.

Product range of the company includes:

Absorbable Sutures

Natural Sutures  

  • Centenial-catgut plain
  • Centenial-catgut chromic

Synthetic Sutures 

  • Centicryl Braided, Coated Polyglycolic Acid (PGA) (Violet & Undyed) 
  • Centicryl Rapid Braided ,Coated Undyed Polyglycolic Acid (PGA)
  • Monosynth Monofilament Synthetic Polydioxanone  
  • Centisorb Poly(glycolide-co-L-lactide) Glacomer 91
  • Braided, Coated with Poly(glycolide-co-L-lactide) 

Non Absorbable Sutures

  • Centilene High Performance Needles for Cardiovascular Surgery 
  • Centlon Black Monofilament Polyamide Atraumatic Needle Suture Combinationsy
  • Centsilk Black Braided Silk, Atraumatic Needle Suture Combinations
  • Centibond High Performance Needles for Cardiovascular Surgery 
  • Centsteel Monofilament 316 LVM Stainless Steel 
  • Centip Ace Temporary Pacemaker Electrode 

Medical Devices

  • T-Suit Female Urinary Incontinency Set
  • Centilene Mesh Non Absprbable Synthetic Knotted Surgical Meshy
  • Skin Stapler Disposable Skin Stapler Manipler S-2 35W
  • Centiclip Titanium Haemostatic Clip For Cardiovascular Surgery
  • Aortic Punch Disposable Aortic Punch for Cardiovascular Anastomosis 
  • Kinfe Cardiovascular Vessel Knife for Cardiovascular Surgery

Awards & Achievements:

  • An ISO 9001:2000 certified company
  • ISO 13485:2003 Certified Company

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-0.09%
1 Week
-0.74%
1 Month
-5.77%
3 Month
+22.78%
6 Month
+3.95%
1 Year
+76.72%
2 Year
+34.75%
5 Year
+4.46%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 11.29 10.56 10.80 10.37 7.72 7.86 6.56 7.98 4.88
Return on Capital Employed (%) 15.80 15.38 13.36 14.22 11.74 14.02 14.84 16.75 15.11
Return on Assets (%) 3.51 3.47 3.66 3.64 2.89 3.17 2.77 3.60 2.06

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 16 17 19 21 23 25 26 28 29
Non Curr. Liab. 4 4 4 3 3 3 3 3 10
Curr. Liab. 23 26 27 31 27 28 26 26 31
Minority Int.
Equity & Liab. 43 48 50 55 53 56 55 57 69
Non Curr. Assets 5 5 5 4 4 4 4 5 11
Curr. Assets 38 43 45 51 49 52 51 52 58
Misc. Exp. not W/O
Total Assets 43 48 50 55 53 56 55 57 69

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 52 54 51 52 51 53 53 56 56
Other Income 0 0 0 0 0 0 0 0 0
Total Income 53 54 51 52 51 53 53 56 56
Total Expenditure -48 -49 -46 -47 -47 -48 -48 -51 -50
PBIDT 5 5 5 5 5 5 5 5 6
Interest -1 -2 -1 -2 -2 -2 -2 -2 -2
Depreciation -1 -1 -1 -1 -1 -1 -1 -1 -2
Taxation -1 -1 -1 -1 -1 -1 -1 -1 -1
Exceptional Items
PAT 2 2 2 2 2 2 2 2 1

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 1 1 0 0 -2 2 2 2
Cash Fr. Inv. -1 -1 0 0 0 -2 -1 -1 -1
Cash Fr. Finan. 0 2 -1 1 1 2 -1 -1 0
Net Change 0 2 -2 1 -1 0 0 -1 0
Cash & Cash Eqvt 1 3 1 2 1 1 1 0 1

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 44.77 44.78 44.78 44.78 44.78 44.78 44.78 44.78 44.78
Public 55.23 55.22 55.22 55.22 55.22 55.22 55.22 55.22 55.22
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Wed, 21 Jul 2021
Shareholding for the Period Ended June 30 2021
Centenial Surgical Suture Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here
Tue, 13 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Certificate under Regulation 74(5) of the SEBI (Depository and Participants) Regulations 2018 for the quarter ended June 30 2021 received from M/s. Purva Shareregistry (I) Private Limited Mumbai MAHARASHTRA SEBI Registration No. : INR000001112 Registrar & Transfer Agent of our Company.

This is for your information and record.
Tue, 13 Jul 2021
Disclosures Of Related Party Transactions Pursuant To Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements [LODR]) Regulations 2015.
Disclosures of Related Party Transactions pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements [LODR]) Regulations 2015 for the half year and year ended on March 31 2021

Technical Scans View Details

Thu, 29 Jul 2021
Stock Outperforming Sectoral Index in both 1 Week and 3 Month Stock Outperforming Sectoral Index in both 1 Week and 3 Month
Decreasing Relative Strength - Benchmark index Decreasing Relative Strength - Benchmark index
Decreasing Relative Strength - Sectoral index Decreasing Relative Strength - Sectoral index
Closing Near 50 EMA Closing Near 50 EMA
Wed, 28 Jul 2021
Strongly Outperforming Benchmark Index Strongly Outperforming Benchmark Index

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 168,733.23 703.00 +2.2%
Divi's Laboratories Ltd. 128,656.69 4,843.80 -1.0%
Dr. Reddy's Laboratories Ltd. 77,707.65 4,672.65 -1.2%
Cipla Ltd. 71,170.06 883.10 -0.8%
Cadila Healthcare Ltd. 58,547.84 572.00 -0.9%
Apollo Hospitals Enterprise Ltd. 58,067.43 4,028.55 0.0%
Aurobindo Pharma Ltd. 53,214.94 908.25 -0.8%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 58.11 703.00 +2.2%
Divi's Laboratories Ltd. Consolidated 2021-03 64.84 4,843.80 -1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 44.73 4,672.65 -1.2%
Cipla Ltd. Consolidated 2021-03 29.59 883.10 -0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 27.44 572.00 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 386.19 4,028.55 0.0%
Aurobindo Pharma Ltd. Consolidated 2021-03 9.98 908.25 -0.8%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.63 703.00 +2.2%
Divi's Laboratories Ltd. Consolidated 2021-03 13.84 4,843.80 -1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.35 4,672.65 -1.2%
Cipla Ltd. Consolidated 2021-03 3.88 883.10 -0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 4.51 572.00 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.64 4,028.55 0.0%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.43 908.25 -0.8%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 703.00 +2.2%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,843.80 -1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,672.65 -1.2%
Cipla Ltd. Consolidated 2020-03 0.18 883.10 -0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 572.00 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,028.55 0.0%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 908.25 -0.8%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 703.00 +2.2%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,843.80 -1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,672.65 -1.2%
Cipla Ltd. Consolidated 2020-03 10.09 883.10 -0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 572.00 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,028.55 0.0%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 908.25 -0.8%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 703.00 +2.2%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,843.80 -1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,672.65 -1.2%
Cipla Ltd. Consolidated 2020-03 12.53 883.10 -0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 572.00 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,028.55 0.0%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 908.25 -0.8%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 703.00 +2.2%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,843.80 -1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,672.65 -1.2%
Cipla Ltd. Consolidated 2020-03 17,131.99 883.10 -0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 572.00 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,028.55 0.0%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 908.25 -0.8%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 703.00 +2.2%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,843.80 -1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,672.65 -1.2%
Cipla Ltd. Consolidated 2020-03 1,546.98 883.10 -0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 572.00 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,028.55 0.0%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 908.25 -0.8%